Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Sanara MedTech Inc.NASDAQ: SMTI
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$2.98M, compared with $4.81M a year earlier. Trailing-twelve-month net change in cash was -$7.09M. Over 3 fiscal years it compounded at +1.1% a year.
Context
- Net change in cash amounted to 9.7% of revenue in FY2025, down 2.7 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$2.98M or moves back toward the trailing-twelve-month quarterly average of -$1.77M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (10.03M) USD
- Year-over-year change
- -193.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.03M) | -193.5% |
| FY2024 | 2024-12-31 | 10.73M | +381.5% |
| FY2023 | 2023-12-31 | (3.81M) | +60.7% |
| FY2022 | 2022-12-31 | (9.69M) | -153.3% |
| FY2021 | 2021-12-31 | 18.2M | — |
Net Change in Cash vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -139.7% is the lowest of 10, against a peer median of +152.0%.
- Net change in cash amounts to 6.6% of revenue for SMTI, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $25.3M USD | +321.0% | — | 7.3% | |
| LTM Mar 2026 | $23.54M USD | +27.1% | -28.1% | 29.6% | |
| LTM Mar 2026 | $10.32M USD | +164.2% | — | 15.1% | |
| LTM Jun 2026 | $9.18M USD | -95.4% | +56.9% | 1.2% | |
| LTM Mar 2026 | $7.95M USD | +1427.0% | -64.7% | 138.5% | |
| LTM Mar 2026 | $7.09M USD | -139.7% | +1.1% | 6.6% | |
| LTM Mar 2026 | $3.93M USD | +152.0% | — | 12.6% | |
| LTM Apr 2026 | CA$1.95M CAD | +1180.1% | -61.8% | 0.3% | |
| LTM Mar 2026 | $398K USD | -114.0% | -29.4% | 0.1% | |
| LTM Mar 2026 | $84.73K USD | +111.8% | — | 0.0% | |
| Peer median (excluding SMTI) | — | +152.0% | -29.4% | 7.3% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.99M) | (8.09M) | (4.44M) | (9.91M) | (27.66M) |
| Depreciation & Amortization | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M |
| Deferred Income Tax | 0 | (5.84M) | 0 | 0 | 0 |
| Stock-Based Compensation | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K |
| Change in Working Capital | (1.18M) | 517.62K | (3.28M) | (911.72K) | (3.84M) |
| Accounts Receivables | (774.81K) | (2.27M) | (1.73M) | (4.54M) | 4.03M |
| Inventory | (1.15M) | (517.27K) | (1.55M) | 1.44M | (431.33K) |
| Accounts Payables | 99.13K | (423.75K) | 575.15K | (471.21K) | 1.24M |
| Other Working Capital | 645.56K | 3.73M | (577.32K) | 2.66M | (8.68M) |
| Other Non-Cash Items | 1.1M | 2.79M | (2.64M) | 1.44M | 9.02M |
| Operating Cash Flow | (4.81M) | (5.55M) | (3.25M) | (23.78K) | 6.79M |
| Capital Expenditures | (750.45K) | (747.02K) | (265.25K) | (229.3K) | (4.63M) |
| Acquisitions (Net) | 0 | (2.52M) | (9.94M) | 0 | 0 |
| Purchases of Investments | (4.53M) | (250K) | 0 | (5.3M) | 9.48M |
| Sales of Investments | 0 | 0 | 0 | 0 | (2.96M) |
| Other Investing Activities | (578.59K) | (598.45K) | 650 | (1.1M) | (10.47M) |
| Investing Cash Flow | (5.28M) | (3.51M) | (10.21M) | (6.61M) | (8.36M) |
| Debt Repayment | 0 | 0 | 9.69M | 19.59M | 0 |
| Common Stock Issued | 28.94M | 0 | 911.37K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (642.53K) | (627.35K) | (958.59K) | (2.15M) | (8.48M) |
| Financing Cash Flow | 28.3M | (627.35K) | 9.64M | 17.37M | (8.48M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 18.2M | (9.69M) | (3.81M) | 10.73M | (10.03M) |
| Free Cash Flow | (5.56M) | (6.3M) | (3.51M) | (253.08K) | 2.16M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.